Blog

Thank you Meg for sharing your plans for Florence Forth Virtual and In-Person! Are you still unsure how to create your Florence Forth Virtual Event? Our new Director of Patient Support, Programs and Administration focuses on the event everyday. We asked her a few questions and found out how she’s celebrating her heroes this year. […]

NO LONGER ENROLLING If you are diagnosed with LGI1 autoimmune encephalitis (LGI1) or are the caregiver of someone with LGI1, you may qualify to participate in this study conducted by Fulcrum Research Group. The goal of the study is to better understand the patient experience with LGI1 autoimmune encephalitis for the purpose of supporting potential […]

Thank you Lisa and Jackie for sharing your 2021 Florence Forth Virtual experiences on social media after the event and for providing expert tips for this year. What makes someone an expert? They’ve done it! The Florence Forth Virtual Event is an opportunity for you to get involved, celebrate your heroes, raise funds and awareness […]

Thank you Rachael for sharing your 2021 Florence Forth Virtual experience! We decided the best way for you to understand what it means to participate in the Florence Forth Virtual event is to ask the experts. What makes someone an expert? They’ve done it! Q1 What did you enjoy about the 2021 Virtual Florence Forth […]

Thank you Team Fledderjohn for sharing your 2021 Florence Forth Virtual experience! We decided the best way for you to understand what it means to participate in the Florence Forth Virtual event is to ask the experts. What makes someone an expert? They’ve done it! Q1 What did you enjoy about the 2021 Virtual Florence […]

Funded by the Autoimmune Encephalitis Alliance, Inc. (AE Alliance) IMPORTANT DATES Application Deadline: May 2, 2022 Award Notification: Early June 2022 The AE Alliance is pleased to announce the call for applications to our second annual AEA Community Seed grant program to support research focused on the diagnosis, management, and outcomes of individuals with autoimmune […]

We are excited to report that the ExTINGUISH Trial will start recruitment in January 2022. This trial is a Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor (NMDAR) Encephalitis and Assess Markers of Disease. This trial is the result of the dedication and hard work of Dr. […]

Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis This paper results from the hard work, dedication, and collaboration between the International NMDAR-antibody Encephalitis Consensus Group and other experts in the field, led by Dr. Margherita Nosadini, Dr. Michael Eyre, and Dr. Ming Lim. The paper aims to answer what treatments are […]

AE Alliance is proud to partner with EUROIMMUN again on the AEA Family Day. Just like last year, EUROIMMUN will be handing out Service Awards for a patient/caregiver and doctor/researcher that had a significant impact on the lives of those affected with AE. EUROIMMUN, whose autoantibody testing panels help patients get an accurate diagnosis, is […]

There are over 100 known autoimmune diseases. Depending on the autoimmune condition, medications may be prescribed to manage symptoms and/or prevent disease progression by suppressing the immune system. The same is true for Autoimmune Encephalitis (AE), starting with first-line immunotherapy (IVIG/PE/steroids) and escalating to second-and third-line therapies, like Rituximab, Cyclophosphamide, and Tocilizumab if first-line therapies […]